Cristina Garcia-Beltran, Rita Malpique, Marianne S Andersen, Firdevs Bas, Judit Bassols, Feyza Darendeliler, Marta Díaz, Barbara Dieris, Flaminia Fanelli, Elke Fröhlich-Reiterer, Alessandra Gambineri, Dorte Glintborg, Abel López-Bermejo, Christopher Mann, Silvia Marin, Barbara Obermayer-Pietsch, Rønnaug Ødegård, Pernille Ravn, Thomas Reinehr, Matteo Renzulli, Cristina Salvador, Viola Singer, Eszter Vanky, Juan Vicente Torres, Melek Yildiz, Francis de Zegher, Lourdes Ibáñez
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. There is no approved pharmacological therapy for PCOS. Standard off-label treatment with oral contraceptives (OCs) reverts neither the underlying pathophysiology nor the associated co-morbidities. Pilot studies have generated new insights into the pathogenesis of PCOS, leading to the development of a new treatment consisting of a fixed, low-dose combination of two so-called insulin sensitisers [pioglitazone (PIO), metformin (MET)] and one mixed anti-androgen and anti-mineralocorticoid also acting as an activator of brown adipose tissue [spironolactone (SPI)], within a single tablet (SPIOMET)...
September 15, 2023: Trials